scholarly journals MICRORNA EXPRESSION PROFILING FOR IDENTIFYING MALIGNANT PLEURAL EFFUSION IN PATIENTS WITH LUNG ADENOCARCINOMA

Respirology ◽  
2018 ◽  
Vol 23 ◽  
pp. 168-168
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Expression Profiling ◽  
Malignant Pleural Effusion ◽  
Microrna Expression

scholarly journals Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion

2018 ◽  
Vol 38 (12) ◽  
pp. 6707-6714 ◽  
Author(s):  
HIROYUKI TAMIYA ◽  
AKIHISA MITANI ◽  
AKIRA SAITO ◽  
TARO ISHIMORI ◽  
MINAKO SAITO ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Expression Profiling ◽  
Malignant Pleural Effusion ◽  
Microrna Expression ◽  
Exosomal Microrna

scholarly journals Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

Oncogene ◽  
2006 ◽  
Vol 25 (31) ◽  
pp. 4300-4309 ◽  
Author(s):  
H-H Yeh ◽  
W-W Lai ◽  
H H W Chen ◽  
H-S Liu ◽  
W-C Su
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion

scholarly journals Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma

2020 ◽  
Vol 133 (21) ◽  
pp. 2532-2542
Author(s):  
Xia Shan ◽  
Lan Zhang ◽  
Dan-Xia Zhu ◽  
Xin Zhou ◽  
Huo Zhang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Expression Profiling ◽  
Microrna Expression ◽  
Diagnostic Biomarkers ◽  
Serum Microrna

scholarly journals A Case of Lung Adenocarcinoma with Wild-Type EGFR Malignant Pleural Effusion Well Controlled by Treatment with Gefitinib

2012 ◽  
Vol 23 ◽  
pp. xi146
Author(s):  
Y. Ueda ◽  
T. Takahama ◽  
K. Sakai ◽  
H. Miyawaki ◽  
T. Yoshikawa ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion ◽  
Wild Type

scholarly journals The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer

2020 ◽  
Author(s):  
Ming-Fang Wu ◽  
Chih-An Lin ◽  
Tzu-Hang Yuan ◽  
Hsiang-Yuan Yeh ◽  
Sheng-Fang Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Cancer Patients ◽  
Patient Outcomes ◽  
Malignant Pleural Effusion ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Anti Cancer ◽  
Cancer Activity

Abstract Background Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that “re-education” of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.

Sign in / Sign up

Export Citation Format

Share Document